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ABSTRACT
Objective: The aim of this study is to evaluate the antidepressant activity of tapentadol using forced swimming test (FST) and tail suspension test 
(TST) experimental models.
Methods: A total of 36 Swiss albino mice (18 for each experimental model) were divided into 3 groups of 6 animals each. In both the experimental 
models, Group I received normal saline – 10 ml/kg (Control group), Groups II and III given tapentadol 20 mg/kg and tapentadol 40 mg/kg, respectively, 
for 7 days, intraperitoneally. On day 7, the drugs were given 40 minutes before conducting the experiment. The duration of immobility was noted and 
compared among all the 3 groups. The observations were analyzed using analysis of variance and Tukey’s post-hoc test.
Results: The duration of immobility was significantly decreased in both the experimental models. Tapentadol groups when compared to control group showed 
statistically significant values, and better results were obtained with tapentadol 20 mg/kg groups in both the models. The mean duration of Immobility was 
34.67 seconds in FST model and 101.00 seconds in TST model when treated with tapentadol 20 mg/kg compared to 102.33 seconds in FST control and 
141 seconds in TST control groups. FST model demonstrates greater antidepressant efficacy of tapentadol (p<0.00) than with TST model (p<0.04).
Conclusion: Tapentadol showed significant antidepressant activity at the dose of 20 mg/kg. The results should be further confirmed by animal 
studies with different experimental models for the evaluation of depression and by human clinical studies, and if found effective, tapentadol can be 
preferred for patients with chronic pain, such as cancer pain.
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INTRODUCTION
Depression
Major depression or simply depression is one of the leading causes of 
global disease burden and disability [1].
Depression is a mental disorder that presents with depressed mood, loss of 
interest or pleasure, feelings of guilt or low self-esteem, disturbed sleep or 
appetite, low energy, and poor concentration lasting for at least 2 weeks [2].
Patients may lose their interest in several common activities which 
were pleasurable to them. They experience loss of appetite, loss 
of concentration, and problem in remembering details or making 
decisions and may think or attempt to suicide. Excessive sleeping, 
loss of sensation, digestive problems, insomnia, fatigue, etc., that are 
resistant to treatment may also be present [3].
Pain
For scientific and clinical purposes, pain is defined by the International 
Association for the Study of Pain (IASP) as “An unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, 
or described in terms of such damage.” This is to be distinguished from 
the term nociception which the IASP defines as the unconscious activity 
induced by a harmful stimulus applied to sense receptors [4].
Chronic pain is defined as pain that has been present for more than 
6 months. It is a chronic pain that is often accompanied by depression [5].
People presenting with chronic pain provide the health practitioner 
with a therapeutic challenge. Depression is a common comorbidity that 
compounds the challenge, often going unrecognized [6].
Patients with major depression have symptoms that reflect changes 
in brain monoamine neurotransmitters, specifically norepinephrine, 
serotonin, and dopamine [7].
Neurotransmitter systems that are used to control pain overlap 
with those which are considered to be the main pathophysiological 
mechanisms in depressive disorders, i.e., serotonergic, noradrenergic, 
and glutamatergic systems [8].
Tapentadol
Tapentadol is a centrally acting analgesic for the treatment of moderate 
to severe acute pain with a dual mode of action: Agonist at the μ-opioid 
receptor (analgesic effect) and as a norepinephrine and 5-HT reuptake 
inhibitor (antidepressant effect) [9].
Furthermore, its binding to the norepinephrine transporter was 
stronger than that of tramadol, whereas its binding to the serotonin 
transporter was less than that of tramadol. Tapentadol was approved 
for the relief of moderate to severe acute pain in patients 18 years of age 
or older, on November 2008 [10].
It is considered similar to tramadol in activity, efficacy, and side-effect 
profile. Like tramadol, it should not be used concurrently with agents 
that enhance monoamine activity or lower the seizure threshold, such as 
monoamine oxidase inhibitors and selective serotonin reuptake inhibitors.
The incidence of serotonin syndrome is less compared to tramadol. The 
major pathway of tapentadol metabolism is conjugation with glucuronic 
acid; ~70% of the dose is excreted in urine in the conjugated form.
METHODS
The study was conducted after taking the necessary approval from 
the Institutional Animal Ethics Committee of J.J.M. Medical College, 
Davangere, in accordance with the CPCSEA guidelines.
Chemicals and drugs
• Tapentadol 20 mg/kg, 40 mg/kg
• Normal saline.
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Selection of animals
A total of 36 Swiss albino mice inbred in the Central Animal House of 
J.J.M. Medical College, Davangere, Karnataka, of either sex and of weight 
between 20 and 40 g, aged 3-4 months were obtained.
The animals were fed with freely accessible standard pellet diet and 
with water ad libitum. They were maintained under standard ambient 
conditions of temperature, humidity, and light (12 h light/12 h dark 
cycle). Experiments were carried out between 9 a.m. and 5 p.m.
Inclusion criteria
• Swiss albino mice of either sex weighing between 20 and 40 g
• Age 3-4 months
• Healthy with normal behavior and activity.
Exclusion crFiteria
• Pregnant and diseased animals were not included in the study
• The mice previously used for any experiments.
Duration of study
Duration of the study was 2 months.
Instruments
Two, of the most commonly used animal screening methods for the 
evaluation of antidepressant activity of potential drugs, were used 
for characterization of antidepressant activity of the putative drug, 
tapentadol. These two are despair-based tests:
I. Forced swimming method apparatus
II. Tail suspension model apparatus.
Procedure
A total of 36 animals (n=36) were used.
They were divided into 6 groups of 6 animals each.
They were evaluated for antidepressant activity using two models.
The animals have free access to standard pellet and water. Test drug 
was administered intraperitoneally for 7 days after dissolving it in 
the normal saline. On day 7, drugs were administered to the mice 
40 minutes before conducting the study.
After completing the experiment, the animals were dried with the cloth 
and returned to the home cage.
Model I: Forced swimming test (FST)
The animals were divided as follows:
Group I: Received 0.1 ml/10 g of normal saline intraperitoneal (i.p) – 
Control (C)
Group II: Received 20 mg/kg of tapentadol (i.p) – TEST 1 (T1)
Group III: Received 40 mg/kg of tapentadol (i.p) – TEST 2 (T2).
Naïve mice were individually forced to swim inside vertical plexiglass 
cylinder (height: 40 cm; diameter: 18 cm, containing 15 cm of water 
maintained at 25°C). After an initial 2 minutes period of vigorous 
activity, each animal assumes a typical immobile posture. The total 
duration of immobility will be recorded after 2 minutes, for 4 minutes 
in a total of 6 minutes test.
The mouse was considered as immobile when it stopped 
struggling/floating motionless and/or making only those movements 
necessary to keep its head above water surface. Shorter immobility 
time is an indicator of the stronger antidepressant effect of the tested 
substance [11].
Water was changed after testing each animal. This test has been 
validated by most current types of antidepressants. After taking the 
animal out of the cylinder, the animal is rehabilitated by drying with the 
cloth and returning them to the home cage (Fig. 1).
Model II: Tail suspension test (TST)
The animals were divided as follows:
Group I: Received 0.1 ml/10 g of normal saline intraperitoneal (i.p) – 
Control (C)
Group II: Received 20 mg/kg of tapentadol (i.p) – TEST 1 (T1)
Group III: Received 40 mg/kg of tapentadol (i.p) – TEST 2 (T2).
On the day of test, mice were hung/suspended individually on a 
horizontal metal bar in upside-down position, 58 cm above a table top, 
after giving the drug, using the adhesive tape placed approximately 
1 cm from the tip of the tail [12].
After an initial vigorous movement, the mouse assumes an immobile 
posture and the period of immobility was recorded after 2 minutes, for 
4 minutes in a total of 6 minutes test. Duration of immobility period was 
compared with those of control group (Fig. 2).
Parameters observed
Duration of immobility was observed after 2 minutes, for 4 minutes in 
a total of 6 minutes in both the experiments. The immobility displayed 
by rodents, when subjected to an unavoidable and inescapable stress, 
and has been hypothesized to reflect behavioral despair, which in 
turn may reflect depressive disorders in humans. Clinically, effective 
antidepressants reduce the immobility that mice display after active 
and unsuccessful attempts to escape when suspended by the tail/made 
float on the surface of water.
Statistical analysis
Mean and standard deviation were used for continuous variables. 
Comparison of all the three groups (intragroup) for each experimental 
Fig. 1: Forced swimming test apparatus  
Fig. 2: Tail suspension test apparatus
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model was done with one-way analysis of variance. Multiple intergroup 
comparisons were done with Tukey’s post-hoc analysis for groupwise 
comparison within each experimental model.
Inter-model comparison of groups was done with Student’s unpaired 
t-test as the data pass normality test.
p<0.05 is considered as the level of statistical significance and p<0.01 is 
considered highly significant.
Statistical analysis was carried out with IBM SPSS version 20 for 
Windows.
RESULTS
The mean duration of immobility of the individual animals of different 
groups of the study for the FST model was noted (Table 1).
The mean duration of immobility of the individual animals of different 
groups of the study for the TST model was noted (Table 2).
Effect of test drug on immobility period in the FST model for 
antidepressant activity
In the FST model of antidepressant activity assessment, there is 
significant reduction in the mean duration of immobility with the 
tapentadol 20 mg/kg-treated group. On intergroup assessment, it is 
found to be of high statistical significance, with p<0.0. It is observed 
that the change in the mean value of duration of immobility is not dose 
dependent (Table 3).
Effect of test drug on immobility period in the TST model for 
antidepressant activity
In the TST model of antidepressant activity assessment, compared to 
control group, there is reduction in the mean duration of immobility 
with the tapentadol 20 mg/kg-treated group and also with the 
tapentadol 40 mg/kg-treated group. It is of statistical significance with 
a p<0.04. Here with the TST experimental model also, it is observed that 
the change in the mean value of duration of immobility was not dose 
dependent (Table 4).
In both the experimental screening models, since the p value is found to 
be statistically significant, multiple intergroup comparisons were done 
with the Tukey’s post-hoc analysis for groupwise comparison within 
each experimental model.
Within the FST experimental model, there is statistically significant 
difference between any 2 groups. It is observed that it is highly 
significant between the control and tapentadol 20 mg/kg-treated 
group. In the same way, within the TST experimental model, the 
statistical significance exists only between the control and tapentadol 
20 mg/kg-treated groups only and it is not so between any of the 2 other 
groups comparison, i.e., control and tapentadol 40 mg/kg groups and 
tapentadol 20 mg/kg- and 40 mg/kg-treated groups.
The results are highly positive with FST experimental model for the 
characterization of antidepressant efficacy of the test drug, tapentadol, 
at both the dosages. However, the results were moderately positive 
with the TST experimental model, that too only with tapentadol when 
treated at the dosage of 20 mg/kg as shown in Graph 1 and 2. Thus, 
the study drug tapentadol has antidepressant activity at the dose of 
20 mg/kg (Tables 5 and 6).
On comparison of the corresponding groups of both the experimental 
models, the t and p values indicate the significant difference in the 
mean duration of immobility, between all the 3 drug groups, which is 
not favorable (Table 7).
DISCUSSION
Depression, which is the most common comorbidity associated 
with pain, both in chronic (such as cancer pain) and acute varieties, 
is often underdiagnosed and undertreated by the physician. Even 
if the depression is diagnosed and treated timely with the drugs, 
they are associated with a latency period for their antidepressant 
effect. Psychological support along with certain medications such as 
sedatives and antidepressants is specifically needed in such a group 
of patients.
Serotonin and norepinephrine are important neurotransmitters 
involved in pain inhibition in descending pain inhibitory tracts. 
Venlafaxine being an antidepressant exerts its mechanism 
mainly by inhibiting reuptake of serotonin and norepinephrine 
like tramadol [13]. In a study conducted in mice using the same 
two experimental models, it was seen that tramadol exhibits 
significant antidepressant activity and it was comparable to tricyclic 
antidepressant, desipramine [14].
Hence, the present study was conducted with tapentadol, which also 
belongs to the same class of drugs as tramadol.
Table 1: The values of mean duration of immobility of the individual animals of different groups of the study
Group→ Group I (control, normal saline) Group II (tapentadol, 20 mg/kg) Group III (tapentadol, 40 mg/kg)
Module→ FST
Mice No.↓ Duration of immobility (in seconds)
1 95 40 79
2 90 25 61
3 102 52 75
4 116 28 92
5 124 37 60
6 87 26 38
FST: Forced swimming test
Table 2: The values of mean duration of immobility of the individual animals of different groups of the study
Group→ Group I (control, normal saline) Group II (tapentadol, 20 mg/kg) Group III (tapentadol, 40 mg/kg)
Module→ TST
Mice no.↓ Duration of immobility (in seconds)
1 136 76 150
2 155 100 126
3 130 124 100
4 186 65 150
5 106 131 110
6 133 110 121
TST: Tail suspension test
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In this study, antidepressant activity of tapentadol was evaluated 
using FST and TST, respectively. In this study, we found significant 
antidepressant activity of tapentadol at a dose of 20 mg/kg, which was 
significant as compared to control group of animals.
Advantages of tapentadol compared to its analog tramadol include:
• It has the least chance of causing serotonin syndrome,
• It used in the treatment of severe diabetic peripheral neuropathic 
pain,
• It carries the minimal potential for pharmacokinetic drug interactions 
(does not inhibit or induces cytochrome P450 enzymes)
• It is a single enantiomer and an active molecule (not a prodrug). 
Hence, it does not require metabolic activation to produce its action
• Tramadol produced somnolence, dizziness, headache, nausea, and 
vomiting [15]
• Tapentadol is a better analgesic than tramadol and has fewer side 
effects compared to tramadol [16].
There is large body of evidence to suggest that the analgesic action of 
tapentadol is mainly related to central monoaminergic mechanism and 
opioids receptor pathway. In vitro studies have shown that tapentadol 
effectively inhibits reuptake of monoamines. It has also been established 
that tapentadol inhibits the reuptake of serotonin in the raphe 
nucleus. Antidepressants mainly act by inhibiting norepinephrine and 
serotonin reuptake and tapentadol by virtue of its property of blocking 
monoaminergic reuptake could be responsible for its antidepressant 
activity evident in this study.
On the other way round, there is also evidence of antidepressant drugs 
showing antinociceptive effect, especially venlafaxine, at the dose, 
10 mg/kg which is supported by the findings of Santhosh Ramakrishna 
et al. and other antidepressants as well by Bomholt et al. [17] and 
Muth-Selbach et al. [18]. These results suggest that the antinociceptive 
activity of these antidepressant drugs could involve opioid mechanisms. 
These observations are in agreement with the findings of Singh 
et al. [19] and Anjaneyulu and Chopra [20].
As the analgesic activity of tapentadol is mediated through μ-receptors, 
it is likely that mirtazapine acts through opioid pathways involving the 
μ-opioid receptors. Apart from that, there is ample evidence to suggest 
that descending pain inhibitory pathways involve monoamines such 
as noradrenaline (NA) and 5-HT, serotonin. Spinal inhibition of pain, 
brought about by inhibiting NA and 5-HT reuptake, is one of the major 
mechanisms of action of opioid analgesics and mirtazapine by virtue of 
its property of blocking monoaminergic reuptake is responsible for its 
antinociceptive activity.
Thus, this study, though preliminary in nature, shows that tapentadol at 
the dose of 20 mg/kg has significant antidepressant effect.
CONCLUSION
Tapentadol showed significant antidepressant activity at the dose of 
20 mg/kg. The results are further to be confirmed by animal studies 
with different experimental models for the evaluation of depression 
and by human clinical studies and if found effective, tapentadol 
could be used in patients with chronic pain, such as cancer pain. 
Table 3: The results obtained after statistical analysis for the FST module
Groups Mean (seconds) Standard deviation F value p value
Group I - Control, normal saline 102.33 14.81 30.29 p<0.000**
Group II - Tapentadol 20 mg/kg 34.67 10.46
Group III - Tapentadol 40 mg/kg 67.50 18.75
**Highly significant, FST: Forced swimming test
Table 4: The results obtained after statistical analysis for the TST module
Groups Mean (seconds) Standard deviation F value p value
Group I – Control, normal saline 141.00 27.04 4.00 p<0.04
Group II – Tapentadol 20 mg/kg 101.00 26.20
Group III – Tapentadol 40 mg/kg 126.17 20.54
TST: Tail suspension test
Table 5: Tukey’s post-hoc analysis for groupwise comparison 
within FST experimental model
Comparison groups Significance
Group I versus II p<0.000**
Group I versus III p<0.003*
Group II versus III p<0.005*
FST: Forced swimming test. **Highly significant, *Significant
Table 6: Tukey’s post-hoc analysis for groupwise comparison 
within TST experimental model
Comparison groups Significance
Group I versus II p<0.03*
Group I versus III p<0.566
Group II versus III p<0.216
TST: Tail suspension test. *Significant
Graph 1: Bar graph representing the results obtained after 
statistical analysis for the forced swimming test and the tail 
suspension test modules
Graph 2: Bar graph representing the comparison of the 
corresponding groups of the forced swimming test and tail 
suspension test experimental models
107
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 103-107
 Pradeep et al. 
Table 7: Master table showing the comparison of the corresponding groups of the FST and TST experimental models, their t and p values
Groups FST TST Unpaired t test
Mean (in seconds) Standard deviation Mean (in seconds) Standard deviation t value p value
Group I 102.33 14.81 141.00 27.04 −3.072 p<0.01
Group II 34.67 10.46 101.00 26.20 −5.76 p<0.000
Group III 67.50 18.75 126.17 20.54 −5.168 p<0.000
FST: Forced swimming test, TST: Tail suspension test
The antidepressant activity of tapentadol can be attributed to its 
norepinephrine and serotonin reuptake inhibiting property, which is 
shared by functionally similar opioid analgesic tramadol, indicating 
the importance of serotonin and norepinephrine in pain as well as 
depression mechanisms.
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